Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the world, associated with symptoms like memory loss and cognitive impairment. Brain lesions caused by the aggregation of amyloid β (Aβ) and neurofibrillary tangles are believed to be the main cause of AD. Therefore, therapeutic agents that control Aβ aggregation may be useful in delaying the onset and progression of AD.